Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Cancer Research Microarray Detects CNVs and LOH on a Single Chip

By BiotechDaily International staff writers
Posted on 01 Apr 2013
Image: The CytoSure Cancer +SNP array (4 x 180k) from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
Image: The CytoSure Cancer +SNP array (4 x 180k) from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
A novel, optimized cytogenetic cancer research microarray system enables reliable, simultaneous detection of both copy number variations (CNVs) and loss of heterozygosity (LOH), and includes software designed to facilitate superior data analysis and interpretation.

Oxford Gene Technology (OGT; Oxfordshire, UK) introduces the “CytoSure Cancer +SNP array” designed to improve the accuracy and efficiency of molecular cancer research. The new microarray combines long oligo array comparative genomic hybridization (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the superior detection of both CNVs) and LOH on a single chip (4 arrays of 180k spots). The array has been optimized in collaboration with Prof. Jacqueline Schoumans from the Lausanne University Hospital (Switzerland), an expert in both aCGH and cancer genomics. Unique to the proprietary CytoSure Cancer +SNP array, any reference sample can be used for analysis without changes to the standard aCGH protocol and, thanks to novel SNP probe chemistry, no restriction digest is required. The capacity to use matched samples is a particular advantage for research into genetic aberrations in cancer, enabling any constitutional abnormalities to be filtered out.

Prof. Schoumans commented, “The development of a new microarray with the capacity to detect both CNVs and LOH simultaneously was vital for improving the efficiency and quality of our research. By working very closely with the technical experts at OGT, we have constructed a new array that allows users to simultaneously screen a wide genomic background for CNVs and LOH, while also enabling in-depth CNV analysis on 1,500 known cancer-associated genes. This approach produces accurate and insightful data, with all aberrations clearly highlighted and filtered using OGT’s excellent CytoSure Interpret Software.”

“The new CytoSure Cancer +SNP array forms part of OGT’s ongoing strategy to design specialized microarrays to help increase our understanding of cancer formation and development [and to facilitate] research into more efficacious, targeted treatments,” added James Clough, Executive Vice President Commercial at OGT. The 60-mer oligonucleotide probes utilized in the array provide a high signal-to-noise ratio and highly sensitive detection; this makes them ideal for research into complex malignant tissues. With OGT’s innovative CytoSure Interpret Software, data analysis is rapid, reliable, and simple to carry out, including updated features (such as the B-allele frequency plot) that have been optimized for the identification of biologically relevant genomic variants in tumor samples.

Related Links:
Oxford Gene Technology
CytoSure Cancer +SNP array
CytoSure Interpret Software



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.